Baird lowered the firm’s price target on NanoString to $4 from $10 and keeps an Outperform rating on the shares. The firm said the reported roughly inline results and announced an exchange for its convertible notes, kicking maturity to 3Q26, alleviating some near-term financing concerns while laying out a path to profitability in 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NSTG:
- NanoString narrows FY23 revenue to $175M-$180M, consensus $180.9M
- NanoString reports Q3 EPS (78c), consensus (58c)
- NSTG Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- NanoString price target lowered to $8 from $14 at Morgan Stanley
- 10x Genomics: UPC declines to issue second injunction against NanoString